Out of 2 analysts covering Vital Therapies Inc (NASDAQ:VTL), 2 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Vital Therapies Inc was the topic in 2 analyst reports since July 8, 2015 according to StockzIntelligence Inc.
The institutional sentiment decreased to 2.56 in Q2 2015. Its down 0.44, from 3 in 2015Q1. The ratio worsened, as 10 funds sold all Vital Therapies Inc shares owned while 6 reduced positions. 14 funds bought stakes while 27 increased positions. They now own 6.90 million shares or 38.69% more from 4.97 million shares in 2015Q1.
Rs Investment Management Co Llc holds 0.3% of its portfolio in Vital Therapies Inc for 1.67 million shares. Gilder Gagnon Howe & Co Llc owns 32,778 shares or 0.01% of their US portfolio. Moreover, Ironwood Financial Llc has 0.01% invested in the company for 860 shares. The Texas-based Next Financial Group Inc has invested 0.01% in the stock. Pdt Partners Llc, a New York-based fund reported 16,683 shares.
Vital Therapies, Inc. is a biotherapeutic company. The company has a market cap of $256.83 million. The Firm is focused on developing a human hepatic cell treatment targeting acute forms of liver failure. It currently has negative earnings. The Company’s product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
The post What to Expect from Vital Therapies Inc (VTL) EPS? appeared first on Octafinance.